Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03189303
Other study ID # DSJ_15010
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 7, 2017
Est. completion date December 14, 2021

Study information

Verified date February 2022
Source DePuy Orthopaedics
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Prospective, global, multicenter study to assess cup position in THA. After written informed consent has been obtained, study evaluations will be collected from the pre-op clinic visit, the operative visit (including discharge), and 6 and 12 weeks postoperatively.


Description:

This is a global, prospective, multi-center study with a planned analysis of a minimum of 176 Subjects. Up to 15 study sites will participate in this study. The primary and secondary endpoints are as follows: Primary endpoint: The primary endpoint is acetabular cup position success at 6 weeks postoperatively. Success is defined as cup inclination and version within 10 degrees of the plan. Secondary endpoints: 1. Inclination success (as defined for the primary endpoint) 2. Version success (as defined for the primary endpoint) 3. 90-day complication rates 4. Change from preoperative baseline for the Harris Hip Score 5. Radiographic Outcomes (based upon: AP Hip, AP Pelvis, and Modified Lauenstein Lateral) 6. Change from preoperative baseline for the EQ-5D-5L (health state, EQ-VAS, and index value, if applicable) 7. Change from 6 week baseline for the Forgotten Joint Score


Recruitment information / eligibility

Status Completed
Enrollment 183
Est. completion date December 14, 2021
Est. primary completion date May 19, 2021
Accepts healthy volunteers No
Gender All
Age group 21 Years and older
Eligibility Inclusion Criteria: 1. All devices are to be used according to the approved indications 2. The patient is undergoing a standard of care hip replacement with the Pinnacle cup and a Corail, Summit, or Actis stem via the posterolateral, anterolateral, or direct lateral approach with the patient in the lateral decubitus position. 3. Individuals who are able to speak, read, and comprehend the Informed Consent Document and willing and able to provide informed patient consent for participation in the study and have authorized the transfer of his/her information to DePuy Synthes. 4. Individuals who are willing and able to complete follow-up as specified by the study protocol. 5. Individuals who are willing and able to complete the Subject Hip Outcomes questionnaires (i.e., FJS-12, EQ-5D-5L and Hip Evaluation) as specified by the study protocol. 6. Individuals who are not bedridden. 7. Individuals who are a minimum age of 21 years at the time of consent. Exclusion Criteria: 1. Active local or systemic infection. 2. Loss of musculature, neuromuscular compromise or vascular deficiency in the affected limb rendering the procedure unjustified. 3. Poor bone quality, such as osteoporosis, where, in the surgeon's opinion, there could be considerable migration of the prosthesis or a significant chance of fracture of the femoral shaft and/or the lack of adequate bone to support the implant(s). 4. Charcot's or Paget's disease. 5. The Subject is a woman who is pregnant or lactating. 6. Subject had a contralateral amputation. 7. Previous partial hip replacement in affected hip. 8. Subject has participated in a clinical investigation with an investigational product (drug or device) in the last three months. 9. Contralateral hip was replaced less than 6 months prior to surgery date 10. Subject is currently involved in any personal injury litigation, medical-legal or worker's compensation claims. 11. Subject was diagnosed and is taking prescription medications to treat a muscular disorder that limits mobility due to severe stiffness and pain such as fibromyalgia or polymyalgia. 12. Subject has a medical condition with less than 2 years of life expectancy. 13. Subject, in the opinion of the Investigator, is a drug or alcohol abuser or has a psychological disorder that could affect their ability to complete patient reported questionnaires or be compliant with follow-up requirements.

Study Design


Related Conditions & MeSH terms

  • Arthritis
  • Osteoarthritis; Rheumatoid Arthritis; Post Traumatic Arthritis

Intervention

Device:
Primary Uncemented Total Hip Arthroplasty
The study devices are the Pinnacle Hip System acetabular cup with a Summit, Actis, or Corail femoral stem

Locations

Country Name City State
Italy Istituto Orthopedico Galeazzi IRCCS Milan
Netherlands Bravis Hospital Bergen op Zoom
Netherlands Maastricht University Medical Center Maastricht
Netherlands Canisius Wilhelmina Hospital Nijmegen
United Kingdom Woodend Hospital Aberdeen Scotland
United Kingdom Glan Clwyd Hospital Rhyl Wales
United States Lowcountry Orthopaedics & Sports Medicine Charleston South Carolina
United States Carolina Orthopaedic and Sports Medicine Center Gastonia North Carolina
United States Orthopaedic Associates of Michigan Grand Rapids Michigan
United States Mount Sinai Hospital New York New York
United States Orthopedic Specialists and Sports Medicine Newark Ohio

Sponsors (1)

Lead Sponsor Collaborator
DePuy Orthopaedics

Countries where clinical trial is conducted

United States,  Italy,  Netherlands,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Composite success of cup inclination and cup version. The primary endpoint is acetabular cup position success at 6 weeks postoperatively. It is a composite endpoint; in order for an individual cup position to be considered successful, the cup's placement must satisfy all of the following criteria at 6 weeks:
Inclination Success: within 10 degrees of the planned inclination
Version Success: within 10 degrees of the planned version
6 weeks
Secondary Inclination success Inclination Success: within 10 degrees of the planned inclination 6 weeks
Secondary Version success Version success: within 10 degrees of the planned version 6 weeks
Secondary 90 day postoperative complication rates The number of subjects and the percentage of subjects with complications at 90 days post-operatively 90 days postoperative
Secondary Harris Hip Score Change from preoperative baseline for the Harris Hip Score Baseline and 6 and 12 weeks postoperative
Secondary Forgotten Joint Score Change from 6 week baseline for the Forgotten Joint Score 6 and 12 weeks postoperative
Secondary EQ-5D-5L dimension score Mean change from baseline for the specified time points Baseline and 6 and 12 weeks postoperative
Secondary EQ-VAS score (subscore of EQ-5D-5L) Mean change from baseline for the specified time points Baseline and 6 and 12 weeks postoperative
Secondary EQ-5D-5L index value (if applicable) Mean change from baseline for the specified time points Baseline and 6 and 12 weeks postoperative
Secondary Radiographic Outcomes Radiographs will be read by an independent radiographic reviewer (IRR) at 6 weeks to act as a baseline measurement to be compared to radiographs taken at later time points (12 weeks). Parameters measured include subsidence, migration, inclination and version angles, osteolysis, and radiolucency. Baseline and 6 and 12 weeks postoperative